Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Stock Rating Upgraded by Wall Street Zen

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) was upgraded by stock analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating in a research note issued on Friday.

Several other analysts have also recently weighed in on the company. Bank of America cut Fresenius Medical Care AG & Co. KGaA from a “neutral” rating to an “underperform” rating in a report on Wednesday, October 15th. Morgan Stanley reaffirmed an “underweight” rating on shares of Fresenius Medical Care AG & Co. KGaA in a research note on Tuesday, August 12th. Zacks Research cut shares of Fresenius Medical Care AG & Co. KGaA from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, November 4th. UBS Group lowered shares of Fresenius Medical Care AG & Co. KGaA from a “sell” rating to an “underperform” rating in a report on Wednesday, October 15th. Finally, Weiss Ratings upgraded shares of Fresenius Medical Care AG & Co. KGaA from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday, October 8th. One equities research analyst has rated the stock with a Buy rating, two have assigned a Hold rating and three have assigned a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Reduce” and a consensus target price of $30.00.

Fresenius Medical Care AG & Co. KGaA Stock Performance

NYSE:FMS opened at $23.92 on Friday. The business’s fifty day moving average is $25.54 and its 200 day moving average is $26.31. The firm has a market cap of $14.04 billion, a price-to-earnings ratio of 19.61, a PEG ratio of 0.64 and a beta of 0.90. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.08 and a current ratio of 1.44. Fresenius Medical Care AG & Co. KGaA has a 52-week low of $21.83 and a 52-week high of $30.46.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) last issued its quarterly earnings data on Tuesday, November 4th. The company reported $0.64 EPS for the quarter, beating the consensus estimate of $0.59 by $0.05. The company had revenue of $5.73 billion during the quarter, compared to analysts’ expectations of $4.72 billion. Fresenius Medical Care AG & Co. KGaA had a net margin of 3.39% and a return on equity of 6.75%. Research analysts predict that Fresenius Medical Care AG & Co. KGaA will post 1.51 EPS for the current year.

Institutional Trading of Fresenius Medical Care AG & Co. KGaA

Institutional investors have recently added to or reduced their stakes in the business. Pzena Investment Management LLC increased its position in shares of Fresenius Medical Care AG & Co. KGaA by 1.0% during the 3rd quarter. Pzena Investment Management LLC now owns 14,816,852 shares of the company’s stock valued at $390,128,000 after purchasing an additional 153,870 shares during the last quarter. Todd Asset Management LLC grew its position in Fresenius Medical Care AG & Co. KGaA by 5.2% during the third quarter. Todd Asset Management LLC now owns 1,303,424 shares of the company’s stock valued at $34,319,000 after buying an additional 64,311 shares during the period. Millennium Management LLC increased its holdings in Fresenius Medical Care AG & Co. KGaA by 50.0% during the first quarter. Millennium Management LLC now owns 1,083,602 shares of the company’s stock valued at $26,982,000 after buying an additional 361,364 shares during the last quarter. Teachers Retirement System of The State of Kentucky increased its holdings in Fresenius Medical Care AG & Co. KGaA by 8.3% during the third quarter. Teachers Retirement System of The State of Kentucky now owns 816,200 shares of the company’s stock valued at $21,491,000 after buying an additional 62,700 shares during the last quarter. Finally, Hennessy Advisors Inc. bought a new position in Fresenius Medical Care AG & Co. KGaA in the second quarter worth approximately $11,479,000. 8.37% of the stock is currently owned by hedge funds and other institutional investors.

About Fresenius Medical Care AG & Co. KGaA

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.